B&K Corporation Limited

Research B&K Corporation Limited (2396.HK) on Bullrun: market cap HKD 450.63M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker2396.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 450.63M
Financial periodQ4 2025
RevenueCNY 522.00K
Net income-CNY 74.52M
Free cash flow-CNY 21.62M
Gross margin92.1%

Valuation Snapshot

latest market cap is HKD 450.63M.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 450.63M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About B&K Corporation Limited

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (PDGF) drugs.

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is B&K Corporation Limited's market cap?

B&K Corporation Limited's market capitalization is HKD 450.63M.